Why did ALSAF.PA stock drop intraday on 19 Jan 2026?

The intraday drop to **€0.80** was driven by thin liquidity, a small market cap and no clear offsetting news. Low volume (**1,883**) amplified selling; fundamentals and negative technical momentum increased pressure. Always check order depth before trading.

What are the short-term forecasts for ALSAF.PA stock?

Meyka AI's model projects **€0.87** in one month and **€0.97** in three months. From **€0.80** today these imply **+8.75%** and **+21.25%**, respectively. Forecasts are projections, not guarantees.

How does Meyka AI rate ALSAF.PA stock and what does it mean?

Meyka AI rates ALSAF.PA with a score out of 100: **63.87 / Grade B — Suggestion: HOLD**. The grade blends benchmark, sector, financials and forecast data. This is informational and not financial advice.

What are the key risks to consider for ALSAF.PA stock?

Key risks include extreme liquidity constraints, negative equity metrics, a **current ratio of 0.03**, and potential dilution. Small-cap medical stocks can gap on low-volume flows and corporate actions, so use tight risk controls.

EU Stocks

ALSAF.PA down 25% intraday on EURONEXT 19 Jan 2026: support at €0.80

ByHuzaifa Zahoor January 19, 2026January 19, 2026

The ALSAF.PA stock plunged 25.23% intraday on EURONEXT to €0.80 on 19 Jan 2026, making it one of the session’s top losers. Trading volume was light at 1,883 shares versus an average of 4,881, amplifying the move. Low liquidity and a weak technical picture pushed the price back to the day low of €0.80, below the 50-day average of €1.88. Investors should note the tiny market cap of €8,666.00 and the upcoming corporate calendar when assessing risk.